The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer.

ABSTRACT: Gastric cancer and colorectal cancer are the leading cause of cancer mortality and have a dismal prognosis. The introduction of biological agents to treat these cancers has resulted in improved outcomes, and combination chemotherapy with targeted agents and conventional chemotherapeutic agents is regarded as standard therapy. Additional newly clarified mechanisms of oncogenesis and resistance to targeted agents require the development of new biologic agents. Aberrant activation of the inositide signaling pathway by a loss of function PTEN mutation or gain of function mutation/amplification of PIK3CA is an oncogenic mechanism in gastric cancer and colorectal cancer. Clinical trials with biologic agents that target the inositide signaling pathway are being performed to further improve treatm

SUBMITTER: Kim HJ 

PROVIDER: S-EPMC4861839 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature